Literature DB >> 30539714

Aging, immune senescence, and immunotherapy: A comprehensive review.

Rawad Elias1, Kevan Hartshorn2, Osama Rahma3, Nina Lin4, Jennifer E Snyder-Cappione5.   

Abstract

The advent of immune checkpoint inhibitors (ICIs) has changed the landscape of cancer treatment. Older adults represent the majority of cancer patients; however, direct data evaluating ICIs in this patient population is lacking. Aging is associated with changes in the immune system known as "immunosenescence" that could impact the efficacy and safety profile of ICIs. In this paper, we review aging-associated changes in the immune system as they may relate to cancer and immunotherapy, with mention of the effect of chronic viral infections and frailty. Furthermore, we summarize the current clinical evidence of ICI effectiveness and toxicity among older adults with cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Checkpoint inhibitors; Frailty; Immune senescence; Immunotherapy; Older adults

Mesh：

Year:  2018        PMID： 30539714     DOI： 10.1053/j.seminoncol.2018.08.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   5.385


  21 in total

1.  Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy.

Authors:  Kaustav P Shah; Haocan Song; Fei Ye; Javid J Moslehi; Justin M Balko; Joe-Elie Salem; Douglas B Johnson
Journal:  Cancer Immunol Res       Date:  2020-04-29       Impact factor: 11.151

Review 2.  Immunotherapy in Older Adults with Cancer.

Authors:  Richard Curtis Godby; Douglas B Johnson; Grant R Williams
Journal:  Curr Oncol Rep       Date:  2019-05-07       Impact factor: 5.075

3.  Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab.

Authors:  Nalee Kim; Jeong Il Yu; Hee Chul Park; Gyu Sang Yoo; Changhoon Choi; Jung Yong Hong; Ho Yeong Lim; Jeeyun Lee; Moon Seok Choi; Jung Eun Lee; Kyunga Kim
Journal:  Cancer Immunol Immunother       Date:  2020-11-24       Impact factor: 6.968

Review 4.  Harnessing big data to characterize immune-related adverse events.

Authors:  Ying Jing; Jingwen Yang; Douglas B Johnson; Javid J Moslehi; Leng Han
Journal:  Nat Rev Clin Oncol       Date:  2022-01-17       Impact factor: 65.011

Review 5.  How the ageing microenvironment influences tumour progression.

Authors:  Mitchell Fane; Ashani T Weeraratna
Journal:  Nat Rev Cancer       Date:  2019-12-13       Impact factor: 60.716

6.  Increased interleukin-17A-producing γδT cells predict favorable survival in elderly patients with LUAD and LUSC.

Authors:  Kele Cui; Xinyu Mei; Min Cheng
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-29       Impact factor: 4.553

Review 7.  Immunotherapy Use in Patients With Lung Cancer and Comorbidities.

Authors:  Mitchell S von Itzstein; Amrit S Gonugunta; Helen G Mayo; John D Minna; David E Gerber
Journal:  Cancer J       Date:  2020 Nov/Dec       Impact factor: 2.074

8.  Vitamin D and Exercise Are Major Determinants of Natural Killer Cell Activity, Which Is Age- and Gender-Specific.

Authors:  Sooyeon Oh; Sukyung Chun; Sena Hwang; Jongseok Kim; Yuri Cho; Jooho Lee; KyuBum Kwack; Sang-Woon Choi
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

9.  Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody.

Authors:  Nalee Kim; Jeong Il Yu; Do Hoon Lim; Jeeyun Lee; Seung Tae Kim; Jung Yong Hong; Won Ki Kang; Woo Kyoung Jeong; Kyoung-Mee Kim
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

10.  Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer.

Authors:  Shijia Zhang; Daniel F Pease; Amit A Kulkarni; Manoj Kumar; Ryan M Shanley; Beibei Xu; Shilvi P Joshi; Manish R Patel
Journal:  Clin Med Insights Oncol       Date:  2021-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.